Exagen Launches Test to Aid in the Detection of ANCA-Associated Vasculitis (AAV)
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the launch of AVISE® Vasculitis AAV, a new testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of ANCA-associated vasculitis (AAV).
ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis is a group of autoimmune diseases characterized by vascular inflammation and damage. Early signs and symptoms vary greatly and are not always indicative of the severity of the disease. Rapid and accurate testing is essential to prevent death and long-term disability. AVISE® Vasculitis AAV is intended for use in patients suspected of ANCA-associated vasculitis, otherwise recognized as small vessel diseases: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
AVISE® Vasculitis AAV enhances Exagen’s catalogue of AVISE® tests, allowing physicians further access to Exagen’s specialty lab dedicated to autoimmune diseases.
“AVISE® Vasculitis AAV exemplifies the rigorous quality that is at the core of all AVISE® testing products. As a company dedicated to autoimmune diseases, this test is yet another example of just how closely Exagen is listening to rheumatologists while advancing our ‘own the hilltop’ strategy by providing diagnostic, prognostic, and monitoring tests to address high unmet needs,” said Ron Rocca, President and CEO of Exagen Inc.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products (CB-CAPs), technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus (SLE). Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit www.Exagen.com.